Binding Database

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Data

Article Title

Organization

Recent Progress in Histone Demethylase Inhibitors.

University of Oxford

Inhibition of Histone Demethylases Offers a Novel and Promising Approach for the Treatment of Cancer and Other Diseases.

Therachem Research Medilab (India)

Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.

Kyoto Prefectural University of Medicine

Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).

University of Copenhagen

Design, synthesis and biological evaluation of pyrimidine base hydroxamic acid derivatives as dual JMJD3 and HDAC inhibitors.

Tsinghua University

Pharmacological inhibition of KDM5A for cancer treatment.

Ningbo University

Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.

University of Oxford

Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).

Hangzhou Normal University

Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.

Nankai University

Identification of the 2-Benzoxazol-2-yl-phenol Scaffold as New Hit for JMJD3 Inhibition.

Institute of Biomolecular Chemistry (Icb)

Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.

The University of Texas M.D. Anderson Cancer Center

From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.

Genentech